IRB #

STUDY00017111

Title

[18F] Fluoroestradiol (FES) PET as a Predictive Measure
for Endocrine Therapy in Patients with Newly Diagnosed
Metastatic Breast Cancer

Principal Investigator

Zahi Mitri

Study Purpose

The purpose of this research study is to test if an imaging drug, not approved by the Food and Drug Administration (FDA), called FES, is useful for evaluating your type of cancer and predicting how well your cancer responds to therapy. This drug is used with a PET/CT scan. The researchers want to see if the PET/CT scan, using the study drug, can improve upon the usual way of choosing treatment for your type of cancer.

Medical Condition(s)

Estrogen receptor positive breast cancer (ER+)

Eligibility Criteria

18 years or older
Newly diagnosed breast cancer that has spread to other parts of the body

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

2 years

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080
knight@ohsu.edu

Sponsor

ECOG-ACRIN

Recruitment End

11/30/2030

Compensation Provided

No


Go Back